The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 18 September 2007, www.theannals.com, DOI 10.1345/aph.1K308.
The Annals of Pharmacotherapy: Vol. 41, No. 11, pp. 1906-1911. DOI 10.1345/aph.1K308
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hawboldt, J.
Right arrow Articles by Bader, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hawboldt, J.
Right arrow Articles by Bader, M.

Intramuscular Methotrexate-Induced Aseptic Meningitis

John Hawboldt, BSP ACPR PharmD

Assistant Professor, School of Pharmacy, Health Sciences Centre; Pharmacotherapy Specialist, Department of Pharmacy, Eastern Health, St. John's, Newfoundland, Canada

Mazen Bader, MD MPh

Clinical Assistant Professor, Faculty of Medicine, Health Sciences Centre

Reprints: Dr. Hawboldt, School of Pharmacy, 300 Prince Philip Dr., Health Sciences Centre, St. John's, NL, Canada A1B 3V6, fax 709/777-7044, hawboldt{at}mun.ca

OBJECTIVE: To report a case of aseptic meningitis induced by intramuscularly administered methotrexate in a patient with rheumatoid arthritis.

CASE SUMMARY: A 62-year-old male presented on 3 separate occasions with symptoms consistent with aseptic meningitis: 2 required hospitalization and 1 was noted during a subsequent ambulatory care visit. Prior to the first episode, the methotrexate dose ranged between 17.5 mg and 20 mg given once weekly over 5 years, 11 months. One month before the patient's first admission, the dose was increased to 22.5 mg. Symptoms on presentation included headache, neck stiffness, and fever. Cerebrospinal fluid testing indicated pleocytosis and low glucose level. Methotrexate was discontinued but was restarted 2 weeks after hospital discharge at the same dose and resulted in a second hospitalization for aseptic meningitis. Upon discharge from the second hospitalization, methotrexate was withheld. After a 2 month withdrawal period and rechallenge, the symptoms returned within 3 days. The drug was then discontinued.

DISCUSSION: Methotrexate-induced aseptic meningitis has been reported in the literature; however, in those cases, the effect occurred only when methotrexate was given via the intrathecal route. We identified 7 relevant articles via a search of MEDLINE, International Pharmaceutical Abstracts, and EMBASE (1970-August 3, 2007): 3 were review articles, 2 were case series, and 2 were case reports. All of the series and reports involved patients with leukemia. The available literature suggests that aseptic meningitis is associated with long-term use of methotrexate or recent dose escalation. A definitive mechanism for methotrexate-induced aseptic meningitis is not known. The Naranjo probability scale indicates a probable relationship between the development of the condition and the methotrexate use in our patient.

CONCLUSIONS: Aseptic meningitis has been previously associated with intrathecal use of methotrexate. Our report describes the first case of aseptic meningitis that occurred in a patient being treated with intramuscular methotrexate.

Key Words: aseptic meningitis, methotrexate, rheumatoid arthritis

Published Online, September 18, 2007. www.theannals.com, DOI 10.1345/aph.1K308





homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.